Aim: To compare the efficacy of 10-20-30 training versus moderate-intensity continuous training (MICT) on HbA1c, body composition and maximum oxygen uptake (V O 2 max) in male patients with type 2 diabetes (T2D). Materials and Methods: Fifty-one male participants with T2D were randomly assigned (1:1) to a 10-20-30 (N = 26) and a MICT (N = 25) training group. Interventions consisted of supervised cycling three times weekly for 10 weeks, lasting 29 minutes (10-20-30) and 50 minutes (MICT) in a local non-clinical setting. The primary outcome was change in HbA1c from baseline to 10-week follow-up. Results: Of 51 participants enrolled, 44 (mean age 61.0 ± 6.8 [mean ± SD] years, diagnosed 7.5 ± 5.8 years, baseline HbA1c 7.4% ± 1.3%) were included in the analysis. Training compliance was 84% and 86% in 10-20-30 and MICT, respectively. No adverse events occurred during the intervention. HbA1c decreased (P <0.001) by 0.5 (95% CI −0.72 to −0.21) percentage points with training in 10-20-30, with no change in MICT. The change in 10-20-30 was greater (P <0.05) than in MICT. Visceral fat mass decreased (P <0.05) only with 10-20-30 training, whereas total fat mass decreased (P <0.01) and V O 2 max increased (P <0.01) with training in both groups. Conclusions: Ten weeks of 10-20-30 training was superior to MICT in lowering HbA1c, and only 10-20-30 training decreased visceral fat mass in patients with T2D. Furthermore, 10-20-30 training was as effective as MICT in reducing total fat mass and increasing V O 2 max, despite a 42% lower training time commitment. K E Y W O R D S glycaemic control, high-intensity interval training, oral glucose tolerance test, skeletal muscle protein adaptations, sprint-interval training.
The menopausal transition is associated with increased prevalence of hypertension, and in time postmenopausal women (PMW) will exhibit a cardiovascular disease risk-score similar to male counterparts. Hypertension is associated with vascular dysfunction, but whether hypertensive PMW have blunted nitric-oxide (NO)-mediated leg vasodilator responsiveness, and whether this is reversible by high-intensity training (HIT) is unknown. To address these questions, we examined the leg vascular conductance (LVC) in response to femoral-infusion of acetylcholine (ACh) and sodium nitroprusside (SNP), and skeletal muscle markers of oxidative stress and NO bioavailability before and after HIT in PMW (12.9±6.0 (mean±SD) years since last menstrual cycle). We hypothesized that ACh- and SNP-induced LVC responsiveness was reduced in hypertensive compared to normotensive PMW and that 10 weeks of HIT would reverse the blunted LVC response and decrease blood pressure (BP).Nine hypertensive (HYP; clinical systolic/diastolic BP 149±11/91±83 mmHg) and 8 normotensive (NORM; 122±13/75±8 mmHg) PMW completed 10 weeks of bi-weekly small-sided floorball training (4-5x3-5 min interspersed by 1-3 min rest periods). Before training, the SNP-induced change in LVC was lower (P<0.05) in HYP compared with NORM. With training, the ACh- and SNP-induced change in LVC at maximal infusion rates i.e. 100 and 6 μg∙min-1∙kg leg mass-1, respectively, improved (P<0.05) in HYP only. Further, training decreased (P<0.05) clinical systolic/diastolic BP (-15±11/-9±7 mmHg) in HYP, and systolic BP (-10±9 mmHg) in NORM. Thus, the SNP-mediated LVC responsiveness was blunted in hypertensive PMW, and reversed by a period of HIT that was associated with a marked decrease in clinical BP.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.